Covance, Inc. (NYSE:CVD)

CAPS Rating: 4 out of 5

A drug development services company providing a range of early stage and late stage product development services on a worldwide basis primarily to the pharmaceutical, biotechnology and medical device industries.

Recs

0
Player Avatar hybridinvestor (26.29) Submitted: 4/26/2010 1:30:34 PM : Outperform Start Price: $59.16 CVD Score: -29.91

Top 2 (other is PPDI) CROs in the market. No debt and solid overall balance sheet. Bought PPDI when it sold off somewhat recently to low 20s and will look to add back into CVD with this CAPS pick a way for me to follow the pick more closely.

Featured Broker Partners


Advertisement